All News

Top news of the day from across the health care landscape.

Psychological factors such as anxiety and depression can directly influence a patient’s experience with cancer-related pain.

Approval was based on results from the phase 3 Impower130 study, which showed atezolizumab in combination with chemotherapy increased overall survival in participants compared with chemotherapy alone.

Emmes, a scientific research company, will support the development of a universal influenza vaccine that could provide longer-lasting protection than the current vaccines available.

Top news of the day from across the health care landscape.

Social interactions between hypothetical health care providers and patients have the power to influence a patient’s perception on the efficacy of a treatment.

The contrast agent is newly indicated to opacify the left ventricular chamber, and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms.

Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis.

Researchers showed that treating multiple myeloma cells with gamma-secretase inhibitors allowed CAR T-cells to more accurately treat cancer tumors.

It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how Specialty Pharmacists can drive the data standardization conversation during the NASP Annual Meeting in Washington, DC.

Since 2005, the CDC has enforced National Influenza Vaccination Week to emphasize the importance of continuing flu vaccination even through the winter months. Although it is the holiday season, the CDC and other organizations want to remind the general public that it is never a bad time to get your flu vaccine. Sam Nass, PharmD, MBS and Walgreens Immunizations Manager weighed in on the subject in an interview with Pharmacy Times®.

The application is based on results from the phase II KEYNOTE-057 trial, which found that pembrolizumab has encouraging activity in patients with high-risk, BCG-unresponsive CIS with or without papillary tumors.

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.

Top news of the day from across the health care landscape.

Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.

The FDA has previously sent warning letters to other companies for illegally selling CBD products that had claimed to prevent, diagnose, mitigate, treat, or cure serious diseases, such as cancer.

The trial identified HIV-1 virus characteristics to predict treatment efficacy with a specific antibody treatment using sequence-based methods.

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss during the future of data in Specialty Pharmacy at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

The approval was based on a phase 3 EDITION JUNIOR trial evaluating children and adolescents, aged 6 to 17 years, living with type 1 diabetes.